Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05762952 · ClinicalTrials.gov registry record · Phase 1

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

A Phase 1 study of Myocardial Ischemia, sponsored by University of Virginia.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT05762952: Recruiting Phase 1 study of Myocardial Ischemia, sponsored by University of Virginia.

NCT05762952 is a Phase 1 study of Myocardial Ischemia that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 40 participants, below the 2,136-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05762952, a Phase 1 study of Myocardial Ischemia, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test the effects of a drug (in the drug class called sodium-glucose cotransporter 2 inhibitors) in women who have symptoms of ischemic heart disease. The main questions the study aims to answer are: Does blood flow in the heart improve with study drug? Participants will be randomly assigned to a 12-week course of the study drug, dapagliflozin 10mg, or placebo. Blood flow in the heart will be assessed using stress cardiac magnetic resonance imaging at baseline and 12 weeks. The researchers will compare the results from the two groups.

Primary Outcome

Myocardial microvascular perfusion, defined as myocardial perfusion reserve as assessed by stress cardiac magnetic resonance imaging

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Dapagliflozin 10mg Tab

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-06-06
Est. Completion 2026-03-31
Phase Phase 1
University of Virginia

449 total trials

What NCT05762952 shows while recruiting

NCT05762952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,136-participant average among 29 other Myocardial Ischemia trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Myocardial Ischemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05762952 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT05762952 about?

NCT05762952 is a clinical study titled "Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease". The goal of this clinical trial is to test the effects of a drug (in the drug class called sodium-glucose cotransporter 2 inhibitors) in women who have symptoms of ischemic heart disease. The main questions the study aims to answer are: Does blood flow in the heart improve with study drug? Partici...

What is the current status of trial NCT05762952?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-06-06. Estimated completion is 2026-03-31.

What conditions does trial NCT05762952 study?

This clinical trial studies the following conditions: Myocardial Ischemia.

What interventions are being tested in trial NCT05762952?

The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10mg Tab (DRUG).

Who is sponsoring clinical trial NCT05762952?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05762952 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocardial Ischemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05762952's enrollment target sits among peer trials

40 25th of 29 higher than 5 of 29 other Myocardial Ischemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myocardial Ischemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05762952, the US trial registry maintained by the National Library of Medicine. NCT05762952 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.